Moderna Inc. agreed to provide as many as 500 million doses of its Covid-19 shot to the program known as Covax in a boost for the global vaccination effort, but only a small fraction of the shipments are due to arrive this year.
The U.S. drugmaker is joining developers including AstraZeneca Plc, Pfizer Inc. and Johnson & Johnson in supplying Covax, which has faced setbacks in its bid to help lower-income nations. The vaccine last week was cleared for emergency use by the World Health Organization, making it eligible for Covax.
